NCT05002699View on ClinicalTrials.gov

Investigating the Impact of Alzheimer's Disease Diagnostics in British Columbia

UnknownOBSERVATIONAL
Enrollment

120

Participants

Timeline

Start Date

February 1, 2019

Primary Completion Date

August 31, 2022

Study Completion Date

March 31, 2023

Conditions
Alzheimer DiseaseDementiaCognitive ImpairmentMild Cognitive Impairment
Interventions
DIAGNOSTIC_TEST

Alzheimer's disease CSF biomarkers

Measurement of amyloid beta peptide 1-42, amyloid beta peptide 1-40, and total tau in cerebrospinal fluid.

Trial Locations (4)

Unknown

Northern Health, Prince George

Providence Health Care, Vancouver

Vancouver Coastal Health, Vancouver

Island Health, Victoria

Sponsors

Collaborators (1)

Health Canada
All Listed Sponsors
collaborator

Brain Canada

OTHER

collaborator

Health Canada

OTHER_GOV

collaborator

Michael Smith Foundation for Health Research

OTHER

collaborator

Women's Brain Health Initiative

UNKNOWN

collaborator

St. Paul's Foundation

UNKNOWN

lead

University of British Columbia

OTHER